John Jacobs compensation by year
NOVAVAX Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $662,868 | $752,500 | $792,917 |
| Bonus | $250,000 | $0 | $0 |
| Stock awards | $2,975,113 | $1,347,500 | $3,545,435 |
| Option awards | $2,996,245 | $2,189,350 | $3,763,292 |
| Non-equity incentive | $267,750 | $684,311 | $640,331 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $149,033 | $113,800 | $114,040 |
| Total | $7,301,009 | $5,087,461 | $8,856,015 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NOVAVAX INC DEF 14A filed April 27, 2026, accession 0001628280-26-027328, and prior-year filings. Open the filing on EDGAR.
How this page was built: the NOVAVAX INC filed document, accession 0001628280-26-027328. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 450,500 | $3,027,360 | — |
| RSU | 166,666 | $1,119,996 | — |
| RSU | 83,197 | $559,084 | — |
| Option | 78,732 | — | $11.92 |
| Option | 281,251 | — | $5.39 |
| Option | 676,000 | — | $7.87 |
Per the Outstanding Equity Awards at Fiscal Year-End table in NOVAVAX INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
NOVAVAX’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| John Jacobs · this page | President and CEO | $8,856,015 |
| Elaine O'Hara | EVP, Chief Strategy Officer | $3,688,276 |
| James Kelly | EVP, Chief Financial Officer and Treasurer | $2,986,228 |
| Mark Casey | EVP, Chief Legal Officer and Corporate Secretary | $2,810,453 |
| Ruxandra Draghia-Akli | Former EVP, Head of Research & Development | $2,303,380 |
| John Trizzino | Former President and Chief Operating Officer | $1,709,950 |
Board service
NOVAVAX board · FY2023–FY2025How this board is paid
Company policy: NOVAVAX pays directors a $55,000 cash retainer and $350,000 in Options and RSUs. As stated in NOVAVAX's FY2025 proxy.
The full NOVAVAX compensation record
free company briefThis page is one person within NOVAVAX's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the NOVAVAX proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order NOVAVAX's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NOVAVAX's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order NVAX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.